Magnitude of visceral leishmaniasis and poor treatment outcome among HIV patients: metaanalysis and systematic review by Mekuriaw Alemayehu Mamo Wubshet Nebiyu Mesfin
HIV/AIDS - Research and Palliative Care Dovepress
O R I G I N A L  R E S E A R C H
open access to scientific and medical research
Open Access Full Text Article
© 2016 Alemayehu et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/
terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the 
work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
HIV/AIDS - Research and Palliative Care 2016:8 75–81submit your manuscript | www.dovepress.com
Dovepress 
75
http://dx.doi.org/10.2147/HIV.S96883
Magnitude of visceral leishmaniasis and poor 
treatment outcome among HIV patients: meta-
analysis and systematic review
Mekuriaw Alemayehu1
Mamo Wubshet1
Nebiyu Mesfin2
1Environmental and Occupational 
Health and Safety Department, 
Institute of Public Health, 2Internal 
Medicine Department, School of 
Medicine, College of Medicine and 
Health Sciences, University of Gondar, 
Gondar, Ethiopia
Correspondence: Mekuriaw Alemayehu 
Institute of Public Health, College of 
Medicine and Health Sciences, University 
of Gondar, PO Box 196, Gondar, Ethiopia 
Tel +251 9 2051 0050 
Email mekuriawbetty@gmail.com
Background: Visceral leishmaniasis (VL) coinfection with HIV/AIDS most often results in 
unfavorable responses to treatment, frequent relapses, and premature deaths. Scarce data are 
available, regarding the magnitude and poor treatment outcomes of VL-HIV coinfection.
Objective: The main objective of this systematic review was to describe the pooled prevalence 
of VL and poor treatment outcome among HIV patients.
Review methods: Electronic databases mainly PubMed were searched. Databases, such as 
Google and Google scholar, were searched for gray literature. Articles were selected based on their 
inclusion criterion, whether they included HIV-positive individuals with VL diagnosis. STATA 11 
software was used to conduct a meta-analysis of pooled prevalence of VL-HIV coinfection.
Results: Fifteen of the 150 articles fulfilled the inclusion criteria. A majority of the study par-
ticipants were males between 25 years and 41 years of age. The pooled prevalence of VL-HIV 
coinfection is 5.2% with 95% confidence interval of (2.45–10.99). Two studies demonstrated 
the impact of antiretroviral treatment on reduction in relapse rate compared with patients who 
did not start antiretroviral treatment. One study showed that the higher the baseline CD4+ cell 
count (.100 cells/mL) the lower the relapse rate. Former VL episodes were identified as risk 
factors for relapse in two articles. In one of the articles, an earlier bout of VL remains significant 
in the model adjusted to other variables.
Conclusion: The pooled prevalence of VL in HIV-infected patients is low and an earlier bout 
of VL and CD4+ count ,100 cells/mL at the time of primary VL diagnosis are factors that 
predict poor treatment outcome.
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Introduction
Visceral leishmaniasis (VL also called “kala-azar”) is a protozoan disease caused 
by the leishmania species complex. An estimated 500,000 new cases of kala-azar 
occur annually.1 HIV infection can lead to reactivation of leishmania infection or 
to symptomatic kala-azar at initial infection; in Europe, the risk of developing VL 
is 100–1,000 times greater for HIV-positive individuals when compared with HIV-
negative individuals.2,3 The HIV/AIDS pandemic has modified the natural history of 
leishmaniasis.4 Kala-azar increases HIV replication and disease progression, mainly 
by chronic immune stimulation.5 Both diseases exert a synergistic detrimental effect 
on the cellular immune response because they target similar immune cells.6
The prevalence of patients with concordant HIV infection and VL in Europe has fallen 
sharply since 1996, when antiretroviral treatment (ART) became standard. In India and 
particularly in Africa, VL-HIV coinfection is emerging. The AIDS pandemic has expanded 
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to rural areas where VL is endemic, with cases of HIV-VL coin-
fection reported in 35 countries.7,8 VL is generally considered 
as an opportunistic infection in patients coinfected with HIV 
and often presents with atypical clinical features.9 VL-HIV 
coinfected patients are at a greater risk of relapse and death. 
Moreover, VL adversely affects the response to ART.6,9
Recent changes in epidemiological trends of HIV and 
leishmania infections possibly lead to a greater degree of 
overlap and a greater risk of coinfection, and they justify 
increased alertness. VL coinfection with HIV/AIDS most 
often results in unfavorable responses to treatment, frequent 
relapses, and premature deaths. Scarce data are available, 
regarding the magnitude and poor treatment outcomes of 
VL-HIV coinfection. This article is a systematic review of 
studies describing the magnitude and factors for poor treat-
ment outcome of VL-HIV coinfected patients.
Methods
First DARE database (http://www.library.UCSF.edu) was 
explored in an attempt to confirm whether systematic review 
or meta-analysis exists and for availability of ongoing projects 
related to the topic. The titles of all appropriate abstracts and titles 
collected from electronic and hand searches were entered into the 
Endnote version 7.0 software (Thomson Reuters, NY, USA).
This systematic review included all papers that were 
published up till August 1, 2015. To ensure scientific rigor, 
the Preferred Reporting of Systematic Reviews and Meta-
Analysis (PRISMA) guidelines10 were used for systematic 
data synthesis. Main sources for the review were electronic 
bibliographic databases, especially MEDLINE. Databases, 
such as Google and Google scholar, were searched, especially 
for gray literature. The search terms used as keywords and/
or MeSH terms are mentioned in Figure 1.
Eligibility criteria
Each study was assessed as to whether it met the eligibility 
criteria as stated in Table 1.
There were no restrictions on date of publication, use 
of secondary prophylaxis, or duration of follow-up in the 
study but there was restriction on publication language. 
The chosen studies were read in full to confirm eligibility. 
Data were extracted directly from the full-length article to 
structured tables containing all of the necessarily variables 
and outcomes’ of interest. The following information was 
extracted: country and period of enrollment, sample size, 
objective of the study, method, VL diagnosis method, study 
participants, and main findings.
Results
The selection process is illustrated in Figure 2. Among 150 
studies, 125 were excluded because they did not meet the 
inclusion criteria following reading titles and/or abstracts. 
Ten more articles were excluded after reading the entire 
article: three were review11–13 and seven14–20 did not evalu-
ate the magnitude of VL-HIV coinfection. Thus, 15 studies 
fulfilled the stated inclusion criteria and constituted the basis 
of this investigation.
Studies and patients
Table S1 summarizes the characteristics of the 1,781 
coinfected patients encompassed by the 15 included stud-
ies. The year of articles publication ranged from 1998 to 
2015. Seven of the articles used retrospective study design, 
four others prospective, two were cross-sectional, one was 
institution based case series, and one both retrospective and 
prospective. Six studies were reported in Ethiopia, three in 
Brazil, three in India, and three in Spain. All 15 articles had 
an enrollment period exclusively after 1989, when highly 
active antiretroviral therapy (HAART) became available. 
Eleven studies stated the proportions of patients receiving 
HAART involving two nucleoside reverse transcriptase 
inhibiters and one or two protease inhibiters, or nonnucleo-
side reverse transcriptase inhibiters at VL diagnosis, or at 
relapse, or both.
(“Leishmaniasis, visceral”) [MeSH Terms] OR (“Leishmaniasis” [All Fields] AND
“visceral”) [All Fields] OR “VL” [All Fields] OR
(“Leishmaniasis” [All Fields] AND “visceral” [All Fields]) OR
(“Leishmaniasis, visceral” [All Fields]) AND
(“hiv infections” [MeSH Terms]) OR (“hiv” [All Fields]) AND
(“infections” [All Fields] OR “hiv infections” [All Fields])
AND (“magnitude” [MeSH Terms] OR “magnitude” [All Fields])       
Figure 1 Terms used in PubMed search.
Abbreviation: VL, visceral leishmaniasis.
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Large proportions of the patients in these studies (74.7%) 
were male and most were young adults: the median or mean 
ages reported varied from 25 years to 41 years. In eight 
of the studies complete CD4+ lymphocyte of the patients 
were reported during diagnosis of VL-HIV coinfection. The 
median or mean CD4+ lymphocyte count in these studies 
ranged from 33 cells/µL to172 cells/µL.21–28
In most of the articles, the diagnosis of VL was made 
on clinical presentation (World Health Organization case 
definition was used as a starting point: fever for .2 weeks 
excluding malaria, in combination with splenomegaly 
and/or wasting29) confirmed by either 1) positive serology 
test if the patient has no VL history or 2) demonstration 
of parasite from spleen or lymph node aspiration. In one 
study,30 the VL diagnosis was done only by using rK39 kit 
(indirect immunofluorescence or rK-39 dipsticks) serologic 
test. Four studies21,22,31,32 also included patients diagnosed 
by only searching for leishmania amastigotes in bone mar-
row/lymph node aspirates. In one study,33 the VL among the 
HIV-infected individuals was diagnosed by ELISA, and the 
result was confirmed by either indirect immunofluorescence 
or Western blot analysis.
The drug used in the treatment of VL is reported for 
59.7% of the treated patients. Of this total, 45% of cases 
(464 patients) were treated with liposomal amphotricine 
B (AmBisome, Gilead Sciences Ltd., Paris, France) drug, 
34.5% with sodium stibogluconate (356 patients), and 
9.9% (102 patients) received a combination of AmBisome 
divided into six equal dose infusions given on alternate 
days, concurrently with 14 days of oral miltefosine. In 
one study,34 pentavalent antimonials (sodium stiboglu-
conate or meglumine antimoniate) was used as first-line 
antileishmanial treatment and liposomal amphotericin B 
(AmBisome) from Gilead Sciences Ltd., Paris, France was 
used as second-line treatment in patients not tolerating 
antimonials and in critically ill patients. A minority of 
patients (0.19%) received pentamidine, and two patients 
(0.19%) were also treated by using amphotericin B lipid 
complex.21
Eight of the 15 studies evaluated the dose of the treat-
ment along with the treatment outcome. One study23 clearly 
showed the limited effectiveness of high-dose AmBisome 
(ranged from 25 mg/kg to 40.5 mg/kg, median of 30 mg/kg). 
Table 1 Inclusion and exclusion criteria of articles reviewed
Inclusion criteria Exclusion criteria
 Presented in an original  
article
 Articles dealing with less than ten cases
 Articles that examined  
VL diagnosis among HIV- 
infected individuals
 Articles dealing with mixed population  
of HIV-infected and uninfected subjects 
unless separated results for HIV 
patients were identified
Non English literaturea
Notes: aLiterature written other than in English language was not included in this 
study.
Abbreviation: VL, visceral leishmaniasis.
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Figure 2 Study selection process.
Abbreviation: VL, visceral leishmaniasis.
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Five of the earlier studies also showed that a total dose of 
20 mg/kg or 25 mg/kg AmBisome was not fully effective 
to cure VL in VL-HIV coinfected patients. In one study,25 
VL patients coinfected with HIV were treated as inpatients 
using a combination of 30 mg/kg body weight AmBisome 
divided into six equal dose infusions given on alternate days, 
concurrently with 14 days of oral miltefosine. The dose of 
miltefosine was calculated according to the patient’s weight 
($25 kg, 50 mg twice daily; weight 12 kg to ,25 kg, 50 mg 
once daily). Completion of the treatment was associated with 
a significant decrease in the size of spleen and liver at the 
time of discharge from the hospital.
A test of cure at the end of the treatment was carried out in 
four of 15 studies. In one study,24 test of cure was not routinely 
performed due to the risks associated with splenic puncture, 
instead “initial cure” was considered following World Health 
Organization35 descriptions of treatment response (when the 
patients showed clinical improvement, cessation of fever, 
reduction in spleen size, and return of appetite at the time 
of discharge).
Three studies24–26 that evaluated VL treatment in HIV 
coinfected patients and one study31 that evaluated the clinical 
presentation of VL-HIV coinfected patients included only 
VL-HIV coinfected patients during their study. Therefore, we 
excluded these papers from meta-analysis of pooled preva-
lence of VL-HIV coinfection. A meta-analysis of results from 
eleven studies evaluating the magnitude of VL-HIV coinfec-
tion is shown in Figure 3. This analysis could consistently 
demonstrate the prevalence of VL-HIV coinfection. The 
pooled estimate of the prevalence from eleven studies is 5.2% 
with confidence interval of (2.45%–10.99%). We used funnel 
plots to visually assess the possibility of publication bias in 
our meta-analysis. The result of our analysis was a symmetric 
funnel plot, and this indicates that there is a possible absence 
of publication bias.
Relapse of VL was reported in eight of the 15 studies. 
Three studies explored the impact of ART on relapse of 
VL.21,24,27 Two studies demonstrated a reduction in relapse 
rate compared with patients who did not undergo ART. 
Only one21 of these studies demonstrated the reduction in 
symptomatic VL relapse in patients with secondary chemo-
prophylaxis after the beginning of HAART. Similarly, one24 
study that  followed patients on ART at VL diagnosis reported 
a decreased risk of mortality.
CD4+ lymphocyte count at VL diagnosis and follow-
up has been studied in relation to risk of relapse. Four 
articles21,24,27,36 compared CD4+ lymphocyte cell counts at 
VL diagnosis between relapsing and nonrelapsing patients as 
a dichotomous variable. Only one27 of these studies showed 
significant difference between these two groups. It was noted 
that the arms with higher CD4+ count (.100 cells/mL) 
had lower relapse rate. In the same study, VL relapses were 
sometimes seen, despite high CD4+ cell counts – in 28% 
of first relapses during follow-up, the preceding CD4+ cell 
count was .200 cells/mL, and in 10% of first relapses, it 
was .350 cells/mL.
Other variables explored in relation to relapse are shown 
in Table S2. Factors, such as age, various clinical findings, 
specific antileishmaniasis treatment given, time from VL 
diagnosis to the introduction of ART, and ART compliance, 
were not substantially different between relapsing and non-
relapsing patients. Concordant tuberculosis27 infection was 
examined in multivariate analysis, and it became an indepen-
dent predictor for the occurrence of VL relapse. Former VL 
bouts were identified as risk factors for relapse in two articles, 
in one of the articles, former VL bouts remain significant in 
multivariate analysis.
Statistical analysis
The statistical quality and the presentation of methods 
and results in many studies were poor. In five studies, the 
Kaplan–Meier method was used in univariant survival 
analysis to analyze the cumulative incidence of outcomes 
(primary VL, relapse VL, and mortality). Two prospective 
and three retrospective cohort studies used Cox regres-
sion for multivariate analysis of independent risk fac-
tors. Eight studies used multivariate logistic regression 
analysis to identify independent predictors. Twelve of 
the abovementioned studies did not conduct collinearity 
assessment (ie, a high degree of correlation between two 
predictive values) or developed a risk score for primary 
or relapse of VL based on their multivariable result. In 
one study,24 collinearity was evaluated by calculating the 
variance inflation factors. In addition, 12 of the above-
mentioned studies did not report a goodness-of-fit test of 
their models during multivariate analysis. In one study,28 
the Hosmer–Lemeshow goodness-of-fit test was used to 
evaluate the model fitness during the multivariate analysis. 
Other studies analyzed their findings by using descriptive 
statistics.
Discussion
This study is a meta-analysis and systematic review of the 
magnitude and poor treatment outcome of VL among HIV-
infected patients. Our main conclusion is that the magnitude 
of VL in HIV-infected patients is low (5.2%). We also found 
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Figure 3 Meta-analysis of pooled prevalence of VL-HIV coinfection.
Note: Weights are from random effects analysis.
Abbreviation: VL, visceral leishmaniasis; ES, estimate.
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that patients who did not face poor treatment outcome 
(relapse or death) showed significantly higher CD4+ count 
at follow-up than patients without poor treatment outcome in 
the course of treatment. Unlike other opportunistic infections, 
there are some reports of VL relapse in patients with a CD4+ 
count .200 cells/mL in Ethiopia. Based on this evidence, 
we can speculate that factors other than a CD4+ cell increase 
are involved in VL control.
It is well known that the arrival of HAART has modified 
the natural history of HIV infection and its opportunistic 
infections, including leishmaniasis.37 The beneficial effect 
of HAART has been demonstrated on other opportunistic 
infections, such as toxoplasmosis, cryptosporidiosis, and 
microsporidiosis.2,38 HAART did not produce the predicted 
decrease in the incidence of kala-azar relapse. Studies that 
were conducted in HAART and pre-HAART era showed a 
similar relapse rate. Only one21 study showed a decrease in 
the relapse rate among patients receiving HAART. None of 
the studies reported a statistically significant difference in 
VL relapse between patients who were receiving and not 
receiving HAART. So far, these disappointing findings are 
not in agreement with a statistically significant association 
between improvements in CD4+ at follow-up and decrease 
in VL relapse. This may be due to the small sample sizes of 
the studies performed, poor patient adherence to ART, or 
insufficient immune response.
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VL affects HIV-1 patients who exhibit a significant dis-
turbance of cellular immunity; however, VL by itself may 
reduce CD4+ lymphocyte count.39 However, a CD4+ count 
.100 cells/mL at VL diagnosis is a potential protective factor 
against relapse, although the analysis of this beneficial effect 
may be complicated by the immune suppression of many of 
the patients included in the studies.
Former bouts of VL were associated with relapse. This 
is also in line with the immune inflammatory theory; it was 
hypothesized that the enhancement of the Th-2 response 
following one early relapse could prevent the later control 
of VL.40
It is important to note that wide ranges of therapeutic 
drugs were utilized for the treatment of VL in the studies 
we have reviewed. There was significant difference in the 
relapse rate with regard to specific VL treatment used. These 
observations do not allow us to disprove the influence of 
treatments used on relapse outcome.
Study limitations
•	 Although we have made an extensive review, our analysis 
was limited to only articles published in English language; 
other studies that were published in different languages 
were excluded. In addition, our analysis includes articles 
with different definitions of cure and different lengths of 
follow-up.
•	 Cure is seldom defined parasitologically in these studies, 
and reinfection is not distinguished from relapse. None of 
the studies reviewed undertook assessment of cure after 
6 months of follow-up.
•	 The evaluated populations were not homogeneous.
•	 The reviewed papers included patients with different 
degrees of immune suppression, different treatment, and 
prophylaxis regimens.
•	 The reviewed articles have differences in study design, 
the type of statistical methods, and the variables included 
in the analysis. These variations may have resulted in 
selection bias or low statistical power, thus hampering 
results.
•	 Most of the reviewed papers used monotherapy to 
treat VL-HIV coinfection, possibly leading to high 
rates of treatment failure and development of resistant 
parasites.
Conclusion
The result of the review suggests that the magnitude of VL 
among HIV-infected patients is low, and previous episodes of 
VL and CD4+ count ,100 cells/mL at the time of primary 
VL diagnosis are potential predictors of relapse. HAART did 
not produce the expected decrease in the incidence of VL 
relapse in the HAART era. This review may help clinicians 
in making decisions and may also help in designing future 
studies, such as, strong surveillance will certainly contribute 
to improved quality of data for decision makers in this com-
plex scenario. More researches are needed, in order to better 
assess the evolution of VL in the HAART era. Clinical trials 
to compare the efficacy of different drugs and their role either 
in the treatment or in prophylaxis are required.
Acknowledgment
The authors thank all the colleagues for their help in find-
ing the gray literature, especially those who are lecturers of 
University of Gondar.
Author contributions
All authors contributed toward data analysis, drafting and 
critically revising the paper and agree to be accountable for 
all aspects of the work.
Disclosure
The authors report no conflicts of interest in this work.
References
 1. Desjeux P. The increase in risk factors for leishmaniasis worldwide. 
Trans R Soc Trop Med Hyg. 2001;95:239–243.
 2. Kubar J, Marty P, Lelievre A, et al. Visceral leishmaniosis in HIV posi-
tive patients: primary infection, reactivation and latent infection: impact 
of the CD4+ T-lymphocyte counts. AIDS. 1998;12:2147–2153.
 3. Paredes R, Munoz J, Diaz I, Domingo P, Gurgui M, Clotet B. Leishma-
niasis in HIV infection. J Postgrad Med. 2003;49:39–49.
 4. Alvar J, Canavate C, Gutierrez-Solar B, et al. Leishmania and human 
immunodeficiency virus coinfection: the first 10 years. Clin Microbiol 
Rev. 1997;10:298–319.
 5. Wolday D, Akuffo H, Demissie A, Britton S. Role of Leishmania 
donovani and its lipophosphoglycan in CD4+ T-cell activation-
induced human immunodeficiency virus replication. Infect Immun. 
1999;67:5258–5264.
 6. Olivier M, Badaro R, Medrano FJ, Moreno J. The pathogenesis of 
Leishmania/HIV co-infection: cellular and immunological mechanisms. 
Ann Trop Med Parasitol. 2003;97(suppl 1):79–98.
 7. Cruz I, Nieto J, Moreno J, Cañavate C, Desjeux P, Alvar J. Leishmania/
HIV co-infections in the second decade. Indian J Med Res. 2006; 
123:357–388.
 8. Desjeux P, Alvar J. Leishmania/HIV co-infections: epidemiology in 
Europe. Ann Trop Med Parasitol. 2003;97(suppl 1):3–15.
 9. WHO. Control of the Leishmaniases. Report of a Meeting of the WHO 
Expert Committee on the Control of Leishmaniasis; March 22–26, 2010; 
Geneva. Geneva: WHO; 2010:1–186.
 10. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for 
reporting systematic reviews and meta-analyses of studies that evalu-
ate health care interventions: explanation and elaboration. PLoS Med. 
2009;6:e1000100.
 11. Diro E, Lynen L, Ritmeijer K, Boelaert M, Hailu A, van Griensven J. 
Visceral leishmaniasis and HIV coinfection in East Africa. PLoS Negl 
Trop Dis. 2014;8(6):e2869.
HIV/AIDS - Research and Palliative Care
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/hivaids---research-and-palliative-care-journal
HIV/AIDS - Research and Palliative Care is an international, peer-
reviewed open-access journal focusing on advances in research in HIV, 
its clinical progression and management options including antiviral 
treatment, palliative care and public healthcare policies to control 
viral spread. The journal welcomes original research, basic science, 
clinical & epidemiological studies, reviews & evaluations, expert 
opinion & commentary, case reports & extended reports. The manu-
script management system is completely online and includes a very 
quick and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
HIV/AIDS - Research and Palliative Care 2016:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
81
Magnitude of visceral leishmaniasis
 12. Cota GF, de Sousa MR, Rabello A. Predictors of visceral leishmaniasis 
relapse in HIV infected patients: a systematic review. PLoS Negl Trop 
Dis. 2011;5(6):e1153.
 13. Lindoso JA, Cota GF, da Cruz AM, et al. Visceral leishmaniasis and HIV 
coinfection in Latin America. PLoS Negl Trop Dis. 2014;8(9):e3136.
 14. Cota GF, de Sousa MR, de Freitas Nogueira BM, et al. Comparison of 
parasitological, serological, and molecular tests for visceral leishma-
niasis in HIV-infected patients: a cross-sectional delayed-type study. 
Am J Trop Med Hyg. 2013;89(3):570–577.
 15. Abdo MG, Elamin WM, Khalil EA, Mukhtar MM. Antimony-resistant 
Leishmania donovani in Eastern Sudan: incidence and in vitro correla-
tion. East Mediterr Health J. 2003;9(4):837–843.
 16. Burza S, Sinha PK, Mahajan R, et al. Risk factors for visceral leishma-
niasis relapse in immunocompetent patients following treatment with 
20 mg/kg liposomal amphotericin B (Ambisome) in Bihar, India. PLoS 
Negl Trop Dis. 2014;8(1):e2536.
 17. Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med 
Int Health. 2001;6(11):849–854.
 18. Murray HW. Prevention of relapse after chemotherapy in a chronic 
intracellular infection: mechanisms in experimental visceral leishma-
niasis. J Immunol. 2005;174:4916–4923.
 19. Murray HW. Treatment of visceral leishmaniasis in 2004. Am J Trop 
Med Hyg. 2004;71(6):787–794.
 20. Takele Y, Abebe T, Weldegebreal T, et al. Arginase activity in the blood 
of patients with visceral leishmaniasis and HIV infection. PLoS Negl 
Trop Dis. 2013;7(1):e1977.
 21. Mira JA, Corzo JE, Rivero A, et al. Frequency of visceral leishma-
niasis relapses in human immunodeficiency virus–infected patients 
receiving highly active antiretroviral therapy. Am J Trop Med Hyg. 
2004;70(3):298–301.
 22. Pineda JA, Gallardo JA, Macías J, et al. Prevalence of and factors 
associated with visceral leishmaniasis in human immunodeficiency 
virus type 1-infected patients in Southern Spain. J Clin Microbiol. 
1998;36:2419–2422.
23. Ritmeijer K, ter Horst R, Chane S, et al. Limited effectiveness of high-
dose liposomal amphotericin B (AmBisome) for treatment of visceral 
leishmaniasis in an Ethiopian population with high HIV prevalence. 
Clin Infect Dis. 2011;53(12):e152–e158.
 24. Burza S, Mahajan R, Sinha PK, et al. Visceral leishmaniasis and HIV 
co-infection in Bihar, India: long-term effectiveness and treatment 
outcomes with liposomal amphotericin B (AmBisome). PLoS Negl 
Trop Dis. 2014;8(8):e3053.
 25. Mahajan R, Das P, Isaakidis P, et al. Combination treatment for visceral 
leishmaniasis patients coinfected with human immunodeficiency virus 
in India. Clin Infect Dis. 2015;61:civ530.
 26. Sinha PK, Griensven J, Pandey K, et al. Liposomal amphotericin B for 
visceral leishmaniasis in human immunodeficiency virus-coinfected 
patients: 2-year treatment outcomes in Bihar, India. Clin Infect Dis. 
2011;53(7):e91–e98.
 27. ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN. Concor-
dant HIV infection and visceral leishmaniasis in Ethiopia: the influence 
of antiretroviral treatment and other factors on outcome. Clin Infect Dis. 
2008;46:1702–1709.
 28. Cota GF, de Sousa MR, de Mendonça AL, et al. Leishmania-HIV 
co-infection: clinical presentation and outcomes in an urban area in 
Brazil. PLoS Negl Trop Dis. 2014;8(4):e2816.
29. WHO. Manual on Visceral Leishmaniasis. Geneva: WHO; 1996.
 30. Yimer M, Abera B, Mulu W, Zenebe Y, Bezabih B. Proportion of visceral 
leishmaniasis and human immune deficiency virus co-infection among 
clinically confirmed visceral leishmaniasis patients at the endemic foci 
of the Amhara National Regional State, North-West Ethiopia. Am J 
Biomed Life Sci. 2014;2(1):1–7.
 31. Lima IP, Müller MC, Holanda TA, Harhay M, Costa CH, Costa DL. 
Human immunodeficiency virus/Leishmania infantum in the first foci 
of urban American visceral leishmaniasis: clinical presentation from 
1994 to 2010. Rev Soc Bras Med Trop. 2013;46(2):156–160.
 32. de La Rosa R, Pineda JA, Delgado J, et al. Incidence of and risk factors 
for symptomatic visceral leishmaniasis among human immunodefi-
ciency virus type 1-infected patients from Spain in the era of highly 
active antiretroviral therapy. J Clin Microbiol. 2002;40:762–767.
 33. Albuquerque LC, Mendonça IR, Cardoso PN, et al. HIV/AIDS-related 
visceral leishmaniasis: a clinical and epidemiological description of 
visceral leishmaniasis in northern Brazil. Rev Soc Bras Med Trop. 
2014;47(1):38–46.
 34. Hurissa Z, Gebre-Silassie S, Hailu W, et al. Clinical characteris-
tics and treatment outcome of patients with visceral leishmaniasis 
and HIV co-infection in northwest Ethiopia. Trop Med Int Health. 
2010;15(7):848–855.
 35. WHO. Indicators for Monitoring and Evaluation of the Kala-Azar 
Elimination Programme. Genave: WHO; 2010.
 36. Mengistu G, Ayele B. Visceral Leishmaniasis and HIV co-infection in 
patients admitted to Gondar University Hospital, Northwest Ethiopia. 
Ethiop J Health Dev. 2007;21(1):53–60. 
 37. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity 
and mortality among patients with advanced human immunodeficiency 
virus infection. HIV Outpatient Study Investigators. N Engl J Med. 
1998;338:853–860.
 38. Carr A, Marrito D, Field A, Vasak E, Cooper DA. Treatment of HIV-
1-associated microsporidiosis and cryptosporidiosis with combination 
antiretroviral therapy. Lancet. 1998;351:256–261.
 39. Berman J. Visceral leishmaniasis in the New World and Africa. Indian 
J Med Res. 2006;123:289–294.
 40. Fernandez Cotarelo MJ, Abellan Martinze J, Guerra Vales JM, et al. 
Effect of highly active antiretroviral therapy on the incidence and clinical 
manifestations of visceral leishmaniasis in HIV infected patients. Clin 
Infect Dis. 2003;37(7):973–977.
 41. Lyons S, Veeken H, Long J. Visceral leishmaniasis and HIV in Tigray, 
Ethiopia. Trop Med Int Health. 2003;8(8):733–739.
